AVENUE THERAPEUTICS, INC.
ATXI evidence brief
What we can confirm
- BioSniper Score:
- 5.7 / 10
- Market Cap:
- $1.4M
- Lead Asset:
- atx-04 (Preclinical)
What it means
What to watch
Prepared research question
What matters most for ATXI—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ATXI
Avenue Therapeutics is a specialty pharmaceutical company developing therapies for neurologic and metabolic disorders, with preclinical candidates BAER-101 (for epilepsy/panic disorders) and ATX-04 (for Pompe disease), and an IV tramadol program for post-operative pain, but faces significant financial constraints and a legal dispute over its former lead candidate AJ201.
Key risk: AJ201 license dispute
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$1.4M
Cash Runway
—
Lead Asset
atx-04 (Preclinical)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 3 pipeline candidates · 3 clinical trials for AVENUE THERAPEUTICS, INC..
Similar companies
Avenue Therapeutics is a specialty pharmaceutical company developing therapies for neurologic and metabolic disorders, with preclinical candidates BAER-101 (for epilepsy/panic disorders) and ATX-04 (for Pompe disease), and an IV tramadol program for post-operative pain, but faces significant financial constraints and a legal dispute over its former lead candidate AJ201.
- Avenue Therapeutics focuses on neurologic diseases and has three main programs: BAER-101 (preclinical α2/3 GABAA PAM for epilepsy/panic disorders), ATX-04 (preclinical clenbuterol for Pompe disease), and IV tramadol (post-operative pain) [pipeline].
- As of 2026-06-30, the company reported cash & equivalents of $1.9M, zero revenue, a net loss of $0.7M, and shareholders' equity of $0.6M [sec].
- The accumulated deficit was approximately $105.5M as of December 31, 2025, with net losses of $2.9M in 2025 and $11.7M in 2024 [sec_mda · as of 2026-03-30].
- Avenue is embroiled in a dispute with AnnJi over the termination of the license for AJ201, its former primary candidate for spinobulbar muscular atrophy [sec_mda · as of 2025-03-31].
- Fortress Biotech controls a majority of voting power and receives significant annual share grants, which dilutes other stockholders [sec_mda · as of 2025-03-31].
What works
- ATX-04 showed meaningful preclinical improvements in Pompe disease, including increased walk distance, respiratory muscle strength, reduced glycogen burden, and improved GAA activity [sec_mda · as of 2026-03-30].
- BAER-101 was originally developed by AstraZeneca through clinical trials involving over 700 patients, providing a foundation of prior safety data [sec_mda · as of 2025-03-31].
- General and administrative expenses decreased from $2.4M to $1.0M in the first half of 2026, reflecting cost control efforts [sec_mda · as of 2026-08-07].
What to weigh
- The company has no approved products and no revenue, relying entirely on future financing to advance its pipeline [sec_mda · as of 2025-05-15].
- Avenue faces a legal dispute with AnnJi over the AJ201 license, which could jeopardize its primary former candidate [sec_mda · as of 2025-03-31].
- Cash reserves are very low ($1.9M as of 2026-06-30) and the company acknowledges it will need additional financing to continue operations [sec_mda · as of 2025-05-15].
- Fortress Biotech's majority voting control and annual share grants create dilution risk for other shareholders [sec_mda · as of 2025-03-31].
From the filings
Quoted directly from source documents.
ATX-04 preclinical data showed improvements in Pompe disease
“Treatment with ATX-04 resulted in improvements in six-minute walk distance, reflecting enhanced functional capacity, as well as increased respiratory muscle strength, including maximal inspiratory pressure.”
SEC MD&A · March 30, 2026
Accumulated deficit as of December 31, 2025
“As of December 31, 2025, we had an accumulated deficit of approximately $105.5 million.”
SEC MD&A · March 30, 2026
Fortress controls majority voting power
“Fortress controls a majority of the voting power of our outstanding capital stock and has the rights to receive significant share grants annually, which will result in dilution of our other stockholders”
SEC MD&A · March 31, 2025
Dispute with AnnJi over AJ201 license
“We have received a purported termination letter from AnnJi, the licensor of our primary product candidate AJ201, and are currently embroiled in a dispute with them regarding such attempted termination.”
SEC MD&A · March 31, 2025
Risks & what to watch (4)›
Key risks
- AJ201 license dispute — AnnJi attempted to terminate the license for AJ201; outcome uncertain and could eliminate the lead candidate [sec_mda · as of 2025-03-31].
- Cash runway insufficient — Only $1.9M cash as of 2026-06-30; company states it needs additional financing to continue [sec_mda · as of 2025-05-15].
- No revenue or approved products — Zero revenue; all programs are preclinical or early-stage, with no near-term approval expected [sec].
- Dilution from Fortress — Fortress receives annual share grants, diluting other stockholders [sec_mda · as of 2025-03-31].
What to watch
- Outcome of the AnnJi license dispute and its impact on the AJ201 program [sec_mda · as of 2025-03-31].
- Pre-IND meeting with FDA for ATX-04 (Pompe disease) and subsequent financing efforts [sec_mda · as of 2026-03-30].
- Ability to raise additional capital given low cash reserves and no revenue [sec_mda · as of 2025-05-15].
- Progress of BAER-101 preclinical development and any partnership developments with AstraZeneca or Baergic [pipeline].
Sources: Pipeline · SEC MD&A · Generated October 9, 2026 · How we verify sources →
Run AVENUE THERAPEUTICS, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available AVENUE THERAPEUTICS, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
D/E 2.47
Lead: Phase 3
3 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Dec 2024Institutional holders
8
Total value held
$385K
| Holder | Shares | Value |
|---|---|---|
| ikarian capital, llc | 140,000 | $280K |
| boothbay fund management, llc | 41,089 | $82K |
| ubs group ag | 7,920 | $16K |
| tower research capital llc (trc) | 3,096 | $6K |
| wells fargo & company/mn | 500 | $1K |
| bank of america corp /de/ | 14 | $28 |
| sbi securities co., ltd. | 9 | $18 |
| concourse financial group securities, inc. | 0 | $0 |
Short Interest
as of May 20, 2026- % of float
- 2.8%
- Days to cover
- 0.7
- Shares short
- 59,696
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ATXI short interestGovernance
Frequently asked questions
What is the AI investment thesis for AVENUE THERAPEUTICS, INC.?
Avenue Therapeutics is a specialty pharmaceutical company developing therapies for neurologic and metabolic disorders, with preclinical candidates BAER-101 (for epilepsy/panic disorders) and ATX-04 (for Pompe disease), and an IV tramadol program for post-operative pain, but faces significant financial constraints and a legal dispute over its former lead candidate AJ201.
What is AVENUE THERAPEUTICS, INC.'s lead drug candidate?
AVENUE THERAPEUTICS, INC.'s most advanced tracked candidate is atx-04 (Preclinical) for Pompe disease.
Who is the CEO of AVENUE THERAPEUTICS, INC.?
Dr. Alexandra MacLean M.D. is the chief executive officer of AVENUE THERAPEUTICS, INC. (ATXI).
Where is AVENUE THERAPEUTICS, INC. headquartered?
AVENUE THERAPEUTICS, INC. (ATXI) is headquartered in Bay Harbor Islands, FL, United States.
What therapeutic areas does AVENUE THERAPEUTICS, INC. focus on?
AVENUE THERAPEUTICS, INC. develops therapies across Rare Disease, Neurology, Cardiovascular, Pain.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.